China pushes AI and biomedicine as strategic growth sectors
Biomedicine and brain-computer interfaces have been identified as strategic priorities for China’s future development.
Chinese Vice Premier Liu Guozhong has called for stronger development of the biomedicine sector and brain-computer interface (BCI) technologies, describing them as strategic industries that will support the Healthy China initiative and China’s future industrial development.
During a visit to Jiangsu Province, Liu called for greater use of AI, big data, and other digital technologies in pharmaceutical research and development to boost innovation and accelerate high-quality growth in the biomedicine sector.
Liu also described brain-computer interfaces as a frontier technology and a strategic area of international competition. Liu called for stronger interdisciplinary collaboration, expanded brain science research, faster breakthroughs in core technologies, and greater original innovation capacity.
The remarks reinforce China’s broader strategy of promoting AI-enabled innovation and emerging technologies to strengthen industrial competitiveness and modernise its healthcare sector.
Why does it matter?
China’s emphasis on AI-powered biomedicine and brain-computer interfaces reflects its strategy of combining healthcare innovation with industrial policy. By encouraging the use of AI in drug discovery while investing in frontier technologies such as BCIs, Beijing is seeking to strengthen domestic innovation and compete in sectors expected to play an important role in future economic growth.
The remarks also underscore the growing geopolitical significance of advanced health technologies. As countries invest in AI, biotechnology and neurotechnology, these fields are increasingly viewed not only as drivers of scientific progress but also as strategic capabilities linked to economic competitiveness, technological sovereignty and national resilience.
Would you like to learn more about AI, tech, and digital diplomacy? If so, ask our Diplo chatbot!